Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Plantform Corporation maintains a patent portfolio with 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This matter is being handled within 1 distinct art unit, reflecting the company's current prosecution effort. The involvement of 1 distinct examiner indicates that the company's current interactions with the patent office are centralized under a single point of review.
The busiest examiner for this portfolio is SHEN, YANXIN NMN, who is overseeing 1 pending office action. Since SHEN, YANXIN NMN is the examiner currently reviewing the company's work, her individual methodology and prior decisions in the Biotechnology & Pharmaceuticals field are factors for the company's immediate strategy. Practitioners must tailor their responses to the specific preferences of this examiner to move the application forward.
Having 1 pending office action across 1 distinct art unit reflects the technical focus for Plantform Corporation at this time. This prosecution environment involves specific variables within the assigned unit. The company can dedicate its attention to the requirements of the examiner to secure its intellectual property rights in this sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHEN, YANXIN NMN | 1 | 84.6% | +26.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19298731 | INHIBITION OF PLANT PROTEASE AED3-1 FOR IMPROVED HETEROLOGOUS PROTEIN PRODUCTION | SHEN, YANXIN NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19298731 | INHIBITION OF PLANT PROTEASE AED3-1 FOR IMPROVED HETEROLOGOUS PROTEIN PRODUCTION | SHEN, YANXIN NMN | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19298731 | INHIBITION OF PLANT PROTEASE AED3-1 FOR IMPROVED HETEROLOGOUS PROTEIN PRODUCTION | SHEN, YANXIN NMN | 1663 | §103§112 | Non-Final OA | — | Pending | Aug 13, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPlantform Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yanxin Nmn Shen has the most, with 1 of Plantform Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.